|
|
|
|
|
|
| |
| Review Period Set for Asthmatx Bronchial System |
| 05/02/2012 |
| |
|
Federal Register Notice: FDA has determined the regulatory review period for Asthmatx, Inc.’s Alair Bronchial Thermoplasty System is 1,743 days for extending a patent which claims the medical device. The Alair system is indicated for treating severe persistent asthma in patients 18 years and older whose asthma is not well controlled with inhaled corticosteroids and long-acting beta agonists. To view this notice, click here.
|
| |
|
| |
| |
Any copying or electronic transfer without written permission is strictly prohibited and will result
in termination of service and prosecution under the federal Copyright Act.
To gain permission to copy this article log on to http://www.copyright.com.
|
|
RSS
